This article is more than 5 years old. Information may no longer be current.

First patient dosed in Kala dry eye treatment trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The first patient has been dosed in a phase 3 trial of Kala Pharmaceuticals’ short-term dry eye treatment KPI-121 0.25%, the company announced in a press release.

The STRIDE 3 multicenter, randomized, double-masked, placebo-controlled, parallel arm trial will compare KPI-121 0.25% to placebo in approximately 900 patients with dry eye, with the primary endpoint being patient report of discomfort severity at day 15. Patients will be dosed four times a day for 14 days.

“If approved, KPI-121 0.25% could be the first FDA- approved product for the short-term treatment of dry eye disease,” Kala’s chief medical officer Kim Brazzell said. “The STRIDE 3 trial design reflects specific modifications to the inclusion/exclusion criteria of our previous trials to address key factors which we believe will improve the probability of success. We anticipate reporting topline results in the fourth quarter of 2019.”